Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
US Army
McKesson
Argus Health
Healthtrust
Citi

Generated: June 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LIRAGLUTIDE RECOMBINANT

« Back to Dashboard

Clinical Trials for Liraglutide Recombinant

Trial ID Title Status Sponsor Phase Summary
NCT00154401 Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 2 This trial is conducted in Europe. The trial is designed to show the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.
NCT00154414 Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 2 This trial is conducted in Japan. The aim of this research trial is to evaluate the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in Japanese subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.
NCT00294723 To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c Terminated Novo Nordisk A/S Phase 3 This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open-label extension (week 104) followed by an additional 156-week continued open-label extension. The total duration of the treatment period is planned to be 260 weeks (5 years).
NCT00318422 Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 3 This trial is conducted globally (the United States of America excepted). This trial is designed to show the effect of treatment with liraglutide when added to existing glimepiride therapy and to compare this to both glimepiride monotherapy and to rosiglitazone as add-on therapy to glimepiride.
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Liraglutide Recombinant

Condition Name

Condition Name for Liraglutide Recombinant
Intervention Trials
Diabetes 109
Diabetes Mellitus, Type 2 101
Obesity 61
Type 2 Diabetes 36
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Liraglutide Recombinant
Intervention Trials
Diabetes Mellitus 207
Diabetes Mellitus, Type 2 180
Diabetes Mellitus, Type 1 32
Overweight 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Liraglutide Recombinant

Trials by Country

Trials by Country for Liraglutide Recombinant
Location Trials
Canada 80
China 60
Denmark 54
Germany 51
India 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Liraglutide Recombinant
Location Trials
California 59
Florida 55
Texas 55
New York 49
Pennsylvania 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Liraglutide Recombinant

Clinical Trial Phase

Clinical Trial Phase for Liraglutide Recombinant
Clinical Trial Phase Trials
Phase 4 97
Phase 3 84
Phase 2/Phase 3 7
[disabled in preview] 55
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Liraglutide Recombinant
Clinical Trial Phase Trials
Completed 166
Recruiting 96
Not yet recruiting 32
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Liraglutide Recombinant

Sponsor Name

Sponsor Name for Liraglutide Recombinant
Sponsor Trials
Novo Nordisk A/S 170
University Medical Centre Ljubljana 8
Sanofi 7
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Liraglutide Recombinant
Sponsor Trials
Other 283
Industry 217
NIH 11
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Daiichi Sankyo
Express Scripts
UBS
Colorcon
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.